| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2/3 data readout example | Phase 2/3 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
phase 2/3 data readout example | Phase 2/3 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
phase 2/3 data readout example | Phase 2/3 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Ocugen, Inc.$1.47
0 (0%)
D 35Pipeline Score Richly Valued Biotech · Clinical
Market Cap
453.62 M
EPS
-0.23
P/E Ratio
-
Value Trade
5.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.53 M
R&D Expenses
11.26 M
Operating CF
-21.79 M
Total Assets
56.91 M
Total Liabilities
51.10 M
Equity
5.80 M
D/E Ratio
12,345
-6.94 %
Week
-25.56 %
1 Month
-16.25 %
3 Month
20.72 %
6 Month
-85.18 %
5 Year
-99.8 %
All Time
Cash Data
Cash Position
31.90 M
Monthly Burn
7.26 M
Runway
2.3 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
3.51 M
52 Week Range
0.80 - 2.73
% held by Insiders
1.69 %
% held by Institutions
34.36 %
Enterprise Value
455.06 M
Total Shares
338.59 M
Short %
32.74 %
Float Shares
322.00 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ocugen, Inc.
644Total events
14Upcoming
186Tier-1 (high impact)
2016 – 2029Coverage
Upcoming catalysts 14
Event history 630
Jul 10, 2026
Q3 2026
Q3 2026
◆Interim AnalysisOCU410STTrial
Interim analysis when 24 subjects complete 8-month follow-up
Stargardt diseasesource ↗
Q3 2026
●BLA SubmissionOCU400 Low DoseApprovedRegulatory Filing
Rolling BLA filing expected in Q3 2026
retinitis pigmentosasource ↗
Q3 2026
●NDA SubmissionOCU400 Low DoseApprovedRegulatory Filing
Rolling BLA submission for OCU400 expected in Q3 2026
retinitis pigmentosasource ↗
Q3 2026
◆End Of Phase 2 MeetingOCU410FDA Meeting
Expect to meet with FDA/EMA to align on Phase 3 study design and reach agreement by Q3 2026
Geographic atrophysource ↗
Jun 13, 2026
◆Oral PresentationPresentation
Clinical Trials at the Summit 2026 - Inherited Retinal Diseases Panel
Jun 4, 2026
◆Oral PresentationPresentation
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference
Jun 2026
◆BLA SubmissionOCU400 Low DoseApprovedRegulatory Filing
Potential BLA and MAA filings for OCU400 by mid-2026
retinitis pigmentosasource ↗
May 26, 2026
May 14, 2026
▼Equity OfferingCorporate
Closing of $130.0 million 6.75% Convertible Senior Notes due 2034, including full exercise of $15.0 million over-allotment option
Drug Pipeline Intelligence
D35
Pipeline Score $52M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 47%
Micro Cap (rank 484 of 912)
Percentile RankOcugen, Inc. faces pipeline headwinds (35/100), with $949M risk-adjusted pipeline value, led by OCU400 Low Dose in Retinitis Pigmentosa (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCU400 Low Dose Small molecule | Retinitis Pigmentosa | Phase 1 | NCT05203939 | 21% | $449M | ACTIVE NOT_RECRUITING | 22 | SLOW | C (41) | Mar 1, 2027 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OCU410 OrphanRare Pediatric | geographic atrophy | Phase 2 | 2026-05-05 | 31% reduction in lesion size; 27% EZ preservation; 20% of patients demonstrated no progression of disease; 75% of subjects showed > 30% reduction in lesion growth compared to control Read More | Ocugen Provides Business Update with First Quarter 2026 Financial Results Read More | |
OCU410 OrphanRare Pediatric | geographic atrophy | Phase 2 | 2026-05-05 | 31% reduction in lesion size; 27% EZ preservation; 20% of patients demonstrated no progression of disease; 75% of subjects showed > 30% reduction in lesion growth compared to control Read More | Ocugen Provides Business Update with First Quarter 2026 Financial Results Read More | |
OCU410 OrphanRare Pediatric | geographic atrophy | Phase 2 | 2026-05-05 | 31% reduction in lesion size; 27% EZ preservation; 20% of patients demonstrated no progression of disease; 75% of subjects showed > 30% reduction in lesion growth compared to control Read More | Ocugen Provides Business Update with First Quarter 2026 Financial Results Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OCGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OCGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OCGNOcugen to Participate in Upcoming July Industry Conferences
Ocugen, Inc. will participate in several industry conferences in July 2026, showcasing its modifier gene therapy platform aimed at treating blindness diseases. Key events include a fireside chat at Piper Sandler's Virtual Ophthalmology Day and presentations at the OIS Retina Innovation Summit and ASRS meeting. These engagements highlight Ocugen's commitment to addressing significant unmet medical needs in ophthalmology.
Read more →OCGNOcugen to Participate in Upcoming June Investor and Industry Conferences
Ocugen, Inc. announced its participation in several upcoming investor and industry conferences in June 2026. The company will present its innovative modifier gene therapy platform, which aims to address inherited retinal diseases. Key events include the Noble Capital Markets Emerging Growth Virtual Equity Conference and the BIO International Convention. A webcast of the presentations will be available on their website.
Read more →OCGNOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes Includes Full Exercise of $15.0 million Over-Allotment Option MALVERN, Pa.
Ocugen, Inc. has announced the successful closing of $130 million in 6.75% Convertible Senior Notes, including a full exercise of an over-allotment option. The financing is expected to provide around $112.6 million in net proceeds, which Ocugen will use to repay its existing loan and support general corporate purposes. The company aims to advance its late-stage gene therapies for treating blindness diseases and targets filing three Biologics License Applications (BLAs) by 2028. However, there are inherent risks associated with the offering and potential dilution effects on existing shareholders.
Read more →OCGNOcugen to Participate in Upcoming May Scientific and Investor Conferences
Ocugen, Inc. will showcase its innovative modifier gene therapy platform at two upcoming conferences in May 2026. The Retina World Congress will feature a session on inherited and rare retinal diseases, while the Stifel 2026 Virtual Ophthalmology Forum will also highlight the company's advancements. These presentations aim to address significant medical needs in treating blindness diseases.
Read more →OCGN▼ -19.5%on this news
Ocugen Provides Business Update with First Quarter 2026 Financial Results
Ocugen reported positive results from its OCU410 Phase 2 trial, showing a significant reduction in lesion size for geographic atrophy. The company completed enrollment for two late-stage trials and plans to submit Biologics License Applications by 2027. A recent $115 million offering is expected to extend its cash runway into 2028, supporting ongoing clinical programs.
Read more →OCGN▼ -19.5%on this newsshared move
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
Ocugen, Inc. has announced the pricing of $115 million in 6.75% Convertible Senior Notes due in 2034. The offering is aimed at qualified institutional buyers and is expected to yield approximately $99.5 million in net proceeds. Funds will be utilized primarily to repay existing debt and for general corporate purposes. The notes will mature in 2034 and have specific terms regarding conversion and redemption.
Read more →OCGNOcugen Announces Private Offering of $115 Million of Convertible Senior Notes
Ocugen, Inc. has announced a private offering of $115 million in Convertible Senior Notes due 2034. The proceeds will primarily be used to repay existing debts and for general corporate purposes. The offering is contingent on market conditions, and there are risks associated with its completion and potential dilution for current shareholders.
Read more →OCGNExcerpts from Preliminary Offering Memorandum Overview We are a biotechnology company focused on discovering, developing, and commercializing novel gene therapies that improve health and offer hope for patients across th
Ocugen, Inc. (OCGN) has published an overview of its biotechnology offerings, particularly focusing on its gene therapy pipelines. The company is making strides with OCU400, which has received favorable opinions from the EMA and is currently enrolled in Phase 3 trials. They anticipate a rolling Biologics License Application (BLA) submission for OCU400 in Q3 2026, with Phase 3 data expected in Q1 2027. Additionally, they are advancing OCU410ST into pivotal trials and aim to submit several BLAs by 2028.
Read more →OCGNOcugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
Ocugen, Inc. will host a conference call on May 5, 2026, at 8:30 a.m. ET to discuss its first quarter financial results and provide business updates. The call will include a pre-market earnings announcement and will be accessible via dial-in and webcast. A replay will be available afterward.
Read more →OCGNOcugen to Present at April 2026 Investor and Industry Conferences
Ocugen, Inc. announced presentations at two upcoming biotech conferences in April 2026. Dr. Shankar Musunuri will present at the Oppenheimer's Innovation on the Island Biotech Summit, while Abhi Gupta will present at the Cell & Gene Meeting on the Mediterranean. The company aims to highlight its gene-agnostic approach to treating blindness diseases and its upcoming BLA submission for OCU400.
Read more →OCGNOcugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
Ocugen has successfully completed dosing ahead of schedule in the Phase 2/3 GARDian3 trial for OCU410ST, a gene therapy for Stargardt disease. The trial enrolled 63 participants and aims to evaluate the therapy's efficacy and safety. Topline results are expected in the second quarter of 2027, with a Biologics License Application planned for mid-2027.
Read more →OCGN▼ -8.6%on this news
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen announced positive 12-month results from its Phase 2 ArMaDa trial for OCU410, a gene therapy for geographic atrophy due to dry age-related macular degeneration. The optimal dose showed a 31% reduction in lesion growth compared to control. The company plans to initiate a Phase 3 trial in Q3 2026, aiming for three BLA filings within three years.
Read more →OCGNOcugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
Ocugen, Inc. will host a webcast on March 24, 2026, to discuss the Phase 2 clinical trial data for OCU410, a modifier gene therapy for geographic atrophy. The event will feature key opinion leaders from renowned institutions who will provide insights and answer questions. The therapy aims to address significant unmet needs in treating late-stage dry age-related macular degeneration.
Read more →OCGN▲ +5.4%on this news
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Ocugen reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its gene therapy programs. The enrollment for the OCU400 Phase 3 trial for retinitis pigmentosa is complete, with topline data expected in 2027. The company also announced positive preliminary data for OCU410 and secured a licensing agreement for OCU400, enhancing its business strategy. Despite a slight increase in net loss per share and decreased cash reserves, Ocugen remains optimistic about its future prospects.
Read more →OCGN▲ +5.4%on this newsshared move
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE OCUGEN, INC. ) C.A. No. 2026-____-___ VERIFIED PETITION FOR RELIEF PURSUANT TO 8 DEL. C. 205 Petitioner Ocugen, Inc. ("Ocugen" or the "Company"), by and through its
Ocugen, Inc. has filed a petition in Delaware seeking court validation of corporate acts and the issuance of stock related to a recent Share Increase Proposal. Due to low stockholder participation, the company faced significant challenges in reaching quorum for annual meetings, prompting the board to adopt measures to facilitate voting. Despite achieving approval of the proposal, legal concerns have arisen which could affect the legitimacy of the shares issued. The petition aims to confirm the approval and mitigate risks stemming from ongoing legal disputes regarding the company's stock structure.
Read more →OCGN▲ +6.6%on this newsshared move
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
Ocugen has completed enrollment for its Phase 3 liMeliGhT trial of OCU400, a gene therapy for retinitis pigmentosa (RP). The trial aims to provide a treatment option for patients with early to late-stage RP, with topline data expected in Q1 2027. Positive long-term data from earlier trials supports the therapy's safety and efficacy.
Read more →OCGNOcugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Ocugen, Inc. will host a conference call on March 4, 2026, at 8:30 A.M. ET to discuss its fourth quarter and full year 2025 financial results. The company, known for its innovative gene therapies for blindness diseases, will also provide a business update during the call. A pre-market earnings announcement will precede the event, and a replay will be available afterward.
Read more →OCGNOcugen Appoints Rita Johnson-Greene to Chief Financial Officer
Ocugen, Inc. has appointed Rita Johnson-Greene as Chief Financial Officer. With over 20 years of healthcare experience, she previously held leadership roles at the Alliance for Regenerative Medicine and Genetix Biotherapeutics. Johnson-Greene's appointment comes as Ocugen prepares to submit its first Biologics License Application this year, marking a significant step in the company's growth.
Read more →OCGNOcugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
Ocugen, Inc. has announced the successful closing of its underwritten registered direct offering, raising $22.5 million through the sale of 15 million shares at $1.50 each. The net proceeds will be utilized for general corporate purposes, extending the company's cash runway into the fourth quarter of 2026. The offering was managed by Oppenheimer & Co. and follows a previously filed registration statement with the SEC.
Read more →OCGN▲ +10.7%on this newsshared move
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
Ocugen, Inc. has announced the pricing of an underwritten offering of 15 million shares of common stock at $1.50 per share, aiming to raise $22.5 million. The offering is expected to close around January 22, 2026, and will be used for general corporate purposes and working capital. The financing is led by RTW Investments.
Read more →OCGNOcugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen announced positive preliminary 12-month data from its Phase 2 ArMaDa clinical trial for OCU410, a gene therapy targeting geographic atrophy secondary to dry age-related macular degeneration. The results showed no serious adverse events and significant reductions in lesion growth. The company plans to file for a Biologics License Application in 2028.
Read more →OCGN▲ +7.3%on this newsshared move
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
Ocugen, Inc. will host a conference call and webcast on January 15, 2026, to discuss data from the OCU410 Phase 2 ArMaDa clinical trial. The event will feature key opinion leaders and Ocugen executives, focusing on the first half of patients who have completed one year of treatment. The webcast will be accessible on the company's investor site.
Read more →OCGN▲ +18.7%on this newsshared move
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
Read more →OCGNOcugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
Ocugen, Inc. announced that CEO Dr. Shankar Musunuri will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. The presentation will focus on the company's modifier gene therapy platform and its clinical development progress. Additionally, Ocugen's executive team will engage with potential partners and investors during the conference.
Read more →OCGNOcugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Read more →OCGNOcugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
Ocugen, Inc. announced that its CEO, Dr. Shankar Musunuri, will present at the NobleCon21 conference. He will discuss the company's advancements towards achieving three BLAs in three years and provide updates on their gene therapy platform for blindness diseases. The event is scheduled for December 3, 2025, at Florida Atlantic University.
Read more →OCGNOcugen Provides Business Update with Third Quarter 2025 Financial Results
Ocugen, Inc. reported its third quarter 2025 financial results, highlighting progress in its clinical trials for gene therapies targeting blindness. The company is on track to submit three Biologics License Applications (BLAs) by 2026 and 2027. A licensing agreement with Kwangdong Pharmaceutical for OCU400 is expected to generate significant revenue. The company is also actively pursuing additional financing and business partnerships.
Read more →OCGNOcugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
Ocugen, Inc. will host a conference call and live webcast on November 5, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide business updates. The company is known for its innovative gene therapies aimed at treating blindness diseases. A replay of the call will be available for 45 days post-event.
Read more →OCGN▲ +5.4%on this news
Ocugen to Present at Industry and Investor Conferences in October 2025
Ocugen, Inc. will present at multiple industry conferences in October 2025, including the Cell & Gene Meeting on the Mesa and the Maxim Growth Summit. The company's leadership aims to showcase their progress towards three BLAs within three years and engage potential partners. The presentations will highlight their innovative gene therapies for blindness diseases.
Read more →OCGN▲ +12.1%on this news· ran to +31% by day 3
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Ocugen, Inc. has entered into a licensing agreement with Kwangdong Pharmaceutical for the exclusive rights to its OCU400 gene therapy for retinitis pigmentosa in Korea. The deal includes upfront fees and sales milestones, with potential revenues projected to reach $180 million in the first decade. This partnership aims to provide new treatment options for patients suffering from vision loss in Korea.
Read more →OCGNOcugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
Ocugen, Inc. announced that CEO Dr. Shankar Musunuri will participate in the H.C. Wainwright 27th Annual Global Investment Conference and Biotech on Tap 2025. These events will provide opportunities to connect with investors and discuss the company's gene therapy platform for blindness diseases. The sessions will include a fireside chat and a panel discussion focused on FDA approval strategies.
Read more →OCGNOcugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
Ocugen, Inc. announced that the European Medicines Agency's CHMP provided positive scientific advice regarding the approval pathway for OCU410ST, a gene therapy for Stargardt disease. The EMA's endorsement allows a single U.S.-based trial to support both BLA and MAA submissions. The ongoing Phase 2/3 trial aims to evaluate the therapy's efficacy in slowing lesion growth and improving visual acuity.
Read more →OCGNOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen, Inc. has announced the successful closing of a $20 million registered direct offering of common stock and warrants. The offering, conducted with Janus Henderson Investors, includes 20 million shares priced at $1.00 each, with warrants exercisable at $1.50. This funding is expected to extend the company's cash runway into 2026, with potential for additional proceeds from warrant exercises.
Read more →OCGNOcugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants MALVERN, Pa.
Ocugen, Inc. has announced a new registered direct offering of common stock and warrants, aiming to raise $20 million. This financing will involve the sale of 20 million shares at a price of $1.00 each, with warrants exercisable at $1.50 per share. The offering is anticipated to close around August 11, 2025, subject to customary conditions. Ocugen's therapies are designed to address significant unmet needs in gene therapies for blindness diseases.
Read more →OCGNOcugen Provides Business Update with Second Quarter 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial Actively do
Ocugen, Inc. has provided a business update alongside its second quarter 2025 financial results, highlighting progress in its clinical trials and partnerships. The company has initiated dosing in its pivotal OCU410ST Phase 2/3 GARDian3 trial focused on Stargardt disease and is on track for BLA submissions with its OCU400 program. Additionally, Ocugen has signed a term sheet for exclusive Korean rights to OCU400 and appointed new board members to enhance its strategic direction. The company's leadership expressed optimism about its gene therapy platform and upcoming developments.
Read more →OCGNOcugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
Ocugen, Inc. has announced new appointments to its Retina Scientific Advisory Board and Executive Leadership Team, aiming to enhance expertise in gene therapies for blindness diseases. The company is focused on solidifying its advisory board with leading retinal surgeons and optimizing its internal leadership to support its goal of filing three BLAs in the next three years. The new appointments are expected to strengthen Ocugen's strategic direction and R&D efforts.
Read more →OCGNOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST
Read more →OCGNOcugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
Read more →OCGN▼ -7.4%on this news
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases - Proposed reverse merger with OrthoCellix, a wholly-owned subs
Carisma Therapeutics has entered into a definitive merger agreement with OrthoCellix to form a company focused on regenerative cell therapies for orthopedic diseases. The combined entity aims to advance OrthoCellix's NeoCart technology, which is designed to repair knee cartilage defects and is preparing for a Phase 3 clinical trial. The merger, which is an all-stock transaction, awaits shareholder approval and is projected to close in the second half of 2025. Carisma will continue as a wholly-owned subsidiary of OrthoCellix post-merger.
Read more →OCGNOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST
Read more →OCGNOcugen To Present at BIO International Convention 2025
Ocugen To Present at BIO International Convention 2025
Read more →OCGN▲ +7.4%on this news· ran to +27% by day 3
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea Upfront fees and near-term development milestone payments totaling up to $11 million
Ocugen, Inc. has announced the signing of a binding term sheet to negotiate a licensing agreement for its OCU400 gene therapy for retinitis pigmentosa in South Korea. The agreement includes potential upfront fees and milestone payments totaling up to $11 million. This partnership aims to leverage the established networks in Korea to enhance patient access to the therapy. However, finalization of the agreement is subject to various uncertainties, including the execution of a definitive contract.
Read more →OCGNOcugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
Read more →OCGNocgn20250509ex991 Ocugen Provides Business Update with First Quarter 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing wel
Ocugen, Inc. reported business updates alongside its first quarter 2025 financial results, highlighting the advancement of its clinical trials for gene therapies targeting retinal diseases. The OCU400 Phase 3 trial for retinitis pigmentosa is progressing well, with potential Biologics License Application filings anticipated by mid-2026. The company also plans to initiate the OCU410ST Phase 2/3 trial for Stargardt disease by mid-2025. While positive data supports the efficacy of their therapies, financial metrics indicate increasing operational costs and a decline in cash reserves.
Read more →OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results
Ocugen Provides Business Update with First Quarter 2025 Financial Results
Read more →OCGNOcugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
Read more →OCGNOcugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
Read more →OCGN▼ -10.2%on this news
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
Read more →OCGN▼ -9.8%on this news
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200
Read more →OCGNOcugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Reached an alignment with FDA on Phase 2 3 pivotal confirmatory clinical trial fo
Ocugen, Inc. has reported positive progress in its clinical trials and business operations during its fourth quarter and full year 2024 update. The company aligned with the FDA to expedite the clinical trial for OCU410ST, aimed at treating Stargardt disease, and demonstrated favorable safety profiles across its ongoing studies, including OCU400 for retinitis pigmentosa. Ocugen has also successfully completed financing efforts and secured a place in the Russell Index. The company targets to submit multiple BLAs within the next few years, reflecting a commitment to addressing significant unmet medical needs in ophthalmology.
Read more →OCGN▼ -7.2%on this newsshared move
Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 and OCU410ST
Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 and OCU410ST
Read more →OCGNOcugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
Read more →OCGNOcugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Read more →OCGNOcugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410
Read more →OCGNOcugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
Read more →OCGN▼ -6.3%on this news
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
Read more →OCGNOcugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Read more →OCGNOcugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
Read more →OCGNData and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Read more →OCGN▲ +6.7%on this news
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
Read more →OCGN▲ +5.1%on this news
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
Read more →OCGNOcugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Read more →OCGN▼ -8.7%on this news
Ocugen Provides Business Update with Third Quarter 2024 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Subsequent to quarter-end, closed $30 million in debt financing OCU400 Phase 3 liMeliGhT clinica
Ocugen, Inc. has provided a business update alongside its third quarter 2024 financial results, confirming significant advancements in its clinical trials for gene therapies targeting eye diseases. The company has secured $30 million in debt financing, extending its cash runway into the first quarter of 2026. Notably, the OCU400 Phase 3 clinical trial is on track for enrollment completion in early 2025, and the OCU410 Phase 2 trial is actively recruiting. Ocugen aims to present new clinical data at an upcoming showcase, reinforcing its commitment to developing innovative ocular therapies.
Read more →OCGN▲ +8.9%on this newsshared move
Ocugen Secures $30 Million in Debt Funding
Ocugen Secures $30 Million in Debt Funding
Read more →OCGN▲ +8.9%on this newsshared move
Ocugen Secures $30 Million in Debt Funding MALVERN, Pa.
Ocugen, Inc. has announced the successful closure of a $30 million credit facility with Avenue Venture Opportunities Fund, aimed at providing capital for corporate purposes and clinical development. This funding is designated to support their three first-in-class modifier gene therapies and is expected to extend the company's financial runway into the first quarter of 2026. The partnership is viewed as a positive move towards advancing Ocugen's mission in the biotechnology sector, particularly in treating blindness-related diseases. This financing marks a strategic step in empowering Ocugen's growth and innovation in gene therapy.
Read more →OCGN▲ +9.2%on this news
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
Read more →OCGNData and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
Read more →OCGNOcugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
Read more →OCGNOcugen to Participate in 2024 Maxim Healthcare Virtual Summit
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
Read more →OCGNOcugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
Read more →OCGNOcugen to Present at the 2024 Cell & Gene Meeting on the Mesa
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
Read more →OCGN▼ -6.1%on this news
Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference
Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference
Read more →OCGN▲ +9.6%on this news
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
Read more →OCGNOcugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
Read more →OCGN▼ -6.9%on this newsshared move
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Read more →OCGNOcugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
Read more →OCGNOcugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Read more →OCGNCourageous Innovation Dedicated to Bringing Game - Changing Gene & Cell Therapies and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally OCGN August 2024 Forward Looking Statements 2 This p
Ocugen (OCGN) is advancing its gene and cell therapy pipeline, focusing on treatments for inherited retinal diseases and other conditions. The company is actively conducting the Phase 3 liMeliGhT trial for its gene therapy candidate OCU400, which targets retinitis pigmentosa. Additionally, Ocugen's work on inhalation vaccines for COVID-19 and flu aims to improve patient access to essential therapies. However, the company also acknowledges the inherent risks and uncertainties in its forward-looking statements and the need for further regulatory approval.
Read more →OCGN▲ +8.5%on this newsshared move
Ocugen Provides Business Update with Second Quarter 2024 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial OCU410 preliminary safety a
Ocugen, Inc. provided a business update alongside its second quarter 2024 financial results, highlighting significant progress in its modifier gene therapy platform. The OCU400 Phase 3 clinical trial for retinitis pigmentosa is currently underway, and the company anticipates safety and efficacy data for OCU410 later this year. The FDA has approved an expanded access program for OCU400, marking it as the first gene therapy candidate for this condition. Additionally, Ocugen raised $32.6 million from a public offering to extend its financial runway into the next year.
Read more →OCGNOcugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
Read more →OCGNWeb 8/4/24, 1:09 PM https://distribute.notified.com/Preview/PnrArticlePreview?r=7184972&l=eng Page 1 of 6 Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa Your publica
Ocugen, Inc. announced that its OCU400 has received FDA approval for an Expanded Access Program aimed at patients with Retinitis Pigmentosa (RP). This program allows eligible individuals with early to advanced stages of RP access to the gene therapy prior to formal approval. OCU400 not only has the potential to improve vision for RP patients but is also regarded as a significant step in addressing unmet medical needs in retinal disease treatment. The company is actively dosing patients in the Phase 3 clinical trial while broadening the availability of OCU400 through the EAP.
Read more →OCGN▼ -5.8%on this newsshared move
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
Read more →OCGNOcugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
Read more →OCGNOcugen, Inc. Announces Proposed Public Offering of Common Stock
Ocugen, Inc. announced its intention to conduct an underwritten public offering of its common stock, aiming to raise funds for general corporate purposes and working capital. The company expects to grant underwriters a 30-day option to purchase additional shares, although the offering is subject to market conditions. This move underscores Ocugen's ongoing commitment to developing innovative gene and cell therapies, but there is inherent uncertainty regarding the completion and financial terms of the offering.
Read more →OCGN▼ -9.8%on this news· ran to -21% by day 3shared move
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
Read more →OCGNOcugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
Read more →OCGNOcugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
Read more →OCGN▼ -6.9%on this newsshared move
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
Read more →OCGNOCUGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Ocugen, Inc. related to claims of materially false and misleading information. The lawsuit pertains to securities purchased between May 2020 and April 2024, with allegations that Ocugen's financial statements were inaccurate and that the company lacked adequate internal controls. Investors have until June 10, 2024, to apply as lead plaintiffs in the action. The firm handling the case, Bragar Eagel & Squire, encourages affected investors to reach out for more information.
Read more →OCGN▼ -7.5%on this newsshared move
Ocugen, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
The Portnoy Law Firm has announced a class action lawsuit on behalf of Ocugen, Inc. investors who incurred losses between May 8, 2020, and April 1, 2024. The lawsuit claims that Ocugen made false and misleading statements about its financial status and failed to maintain adequate financial reporting controls. Investors are advised to contact the law firm for a complimentary case evaluation and to discuss their legal rights before the deadline of June 10, 2024.
Read more →OCGN▲ +8.8%on this news
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
Read more →OCGNOcugen to Present at BIO International Convention 2024
Ocugen to Present at BIO International Convention 2024
Read more →OCGNOcugen Set to Join Russell 3000® Index Effective June 28, 2024
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
Read more →OCGNOcugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
Read more →OCGN▲ +15.3%on this newsshared move
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
Read more →OCGN▼ -6.1%on this newsshared move
Ocugen Provides Business Update with First Quarter 2024 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET All three first-in-class modifier gene therapy product candidates currently in the clinic with O
Ocugen, Inc. has announced a business update alongside its first quarter 2024 financial results. The company is advancing its lead product candidate, OCU400, with FDA clearance for a Phase 3 trial, targeting broad retinitis pigmentosa indications. They aim to begin patient dosing in Q2 2024 and are also planning to expand trials for other genetic conditions. Financial results indicate a cash decrease but a reduction in operating expenses compared to last year.
Read more →OCGN▲ +13.8%on this news· ran to +25% by day 3shared move
Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline
The Portnoy Law Firm has initiated a lawsuit on behalf of investors who purchased Ocugen, Inc. securities, urging them to explore options for recovering losses. This follows disclosure of significant accounting errors by the company related to its financial statements, necessitating restatements of fiscal results since 2020. As a consequence, Ocugen admitted to material weaknesses in its internal controls, leading to a noticeable decline in its stock price by over 10%. Investors are encouraged to contact the firm for a complimentary case evaluation regarding their legal rights.
Read more →OCGNOcugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Read more →OCGNOcugen to Present at May 2024 Investor Conferences
Ocugen to Present at May 2024 Investor Conferences
Read more →OCGNOcugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
Read more →OCGN▼ -5%on this newsshared move
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
Read more →OCGN▲ +8.6%on this newsshared move
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
Read more →OCGN▲ +8.5%on this newsshared move
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Read more →OCGN▲ +8.5%on this newsshared move
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Read more →OCGNOcugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Read more →OCGNOcugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
Read more →OCGNOCUGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Ocugen, Inc. filed in the U.S. District Court for the Eastern District of Pennsylvania. The lawsuit pertains to claims made by investors who purchased Ocugen securities between May 8, 2020, and April 1, 2024. The complaint alleges that Ocugen failed to disclose material misstatements regarding its financial performance and internal controls, which misled investors about the company's business conditions. Investors have until June 10, 2024, to apply to be appointed as lead plaintiffs.
Read more →OCGN▲ +5.3%on this newsshared move
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Read more →OCGNOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication MALVERN, Pa.
Ocugen, Inc. has received U.S. FDA clearance to initiate a Phase 3 clinical trial for OCU400, a novel gene therapy for retinitis pigmentosa (RP). This marks a significant milestone as OCU400 is the first gene therapy designed to address a broad range of RP indications. The trial will include 150 participants and employ a new mobility assessment method to measure treatment effectiveness. This development provides hope for a condition that currently has limited treatment options.
Read more →OCGN▲ +21.2%on this newsshared move
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Read more →OCGN▲ +9.1%on this news· ran to +36% by day 3shared move
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
Ocugen, Inc. is under investigation by Bragar Eagel & Squire, P.C. on behalf of its stockholders for potential violations of federal securities laws. This follows the company's disclosure of a material weakness in its financial reporting controls, specifically concerning the accounting for collaboration-related costs. The announcement led to a notable decline in Ocugen's stock price, which fell over 10% during intraday trading on April 2, 2024. Investors are encouraged to contact the law firm if they have suffered losses related to their investments in Ocugen.
Read more →OCGN▼ -10.4%on this newsshared move
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 Conference Call and Webcast Today at 8 30 a.m. ET Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 cli
Ocugen provided a business update featuring key financials for 2023, highlighting FDA alignment for the Phase 3 clinical trial of OCU400, the first gene therapy program to receive a broad indication for retinitis pigmentosa. The company also received RMAT designation, expected to enhance the therapy's development timeline. Dosing has been completed for initial cohorts of its OCU410 and OCU410ST gene therapy trials targeting geographic atrophy and Stargardt disease. However, the company is facing challenges, including the need for financial restatement and a significant decrease in cash resources compared to the previous year.
Read more →OCGN▼ -6.1%on this newsshared move
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST
Read more →OCGN▼ -6.1%on this newsshared move
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
Read more →OCGNOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer MALVERN, Pa
Ocugen, Inc. has appointed Dr. Huma Qamar, MD, MPH as its new Chief Medical Officer. Dr. Qamar brings extensive experience from Ivy League institutions and has been instrumental in overseeing previous clinical trials. Her role will focus on enhancing Ocugen's clinical development and bringing innovative gene therapies to the market. The company's leadership expresses confidence in her capabilities to advance their ongoing programs.
Read more →OCGN▲ +5.7%on this newsshared move
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
Read more →OCGNOcugen to Present at Investing in Cures Summit
Ocugen to Present at Investing in Cures Summit
Read more →OCGNOcugen Clinical Showcase Webcast Now Available
Ocugen Clinical Showcase Webcast Now Available
Read more →OCGN▲ +13.3%on this news· ran to +25% by day 1shared move
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
Read more →OCGN▼ -6%on this news· ran to -25% by day 1shared move
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
Read more →OCGNOcugen to Present at 2024 BIO CEO & Investor Conference
Ocugen to Present at 2024 BIO CEO & Investor Conference
Read more →OCGNocgn-20240221xex991 Courageous Innovation Clinical Showcase
Ocugen's latest showcase highlighted advancements in its gene therapy platform, particularly the OCU400 program aimed at treating inherited retinal diseases. The company plans to commence a Phase 3 clinical trial for OCU400 by March/April 2024, driven by positive results from earlier phases. Additionally, Ocugen emphasized its commitment to addressing unmet medical needs through innovative therapies and aims to maximize patient access globally. The expected growth in their pipeline underscores their proactive approach in the biotechnology sector.
Read more →OCGN▲ +9.3%on this news· ran to +70% by day 3
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
Read more →OCGNOcugen to Present at Pharma Market Research Conference
Ocugen to Present at Pharma Market Research Conference
Read more →OCGN▼ -6.4%on this news
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
Read more →OCGN▲ +6.9%on this news· ran to +42% by day 3
Ocugen Gains FDA Alignment on Key Aspects of OCU400 - Modifier Gene Therapy - Pivotal Phase 3 Study Design MALVERN, Pa.
Ocugen, Inc. has received alignment from the FDA regarding key elements of the Phase 3 clinical trial design for its gene therapy OCU400, aimed at treating Retinitis Pigmentosa (RP) caused by RHO mutations. This development, alongside existing orphan drug and RMAT designations, positions the company to advance product development confidently. Ocugen is set to initiate the Phase 3 trial in early 2024, which will expand its patient enrollment strategy. This trial targets an important part of the RP patient community, potentially addressing significant unmet needs.
Read more →OCGN▲ +5.8%on this news· ran to +21% by day 3shared move
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
Read more →OCGNOcugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Read more →OCGNOcugen CEO to Present at NobleCon19 – Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
Read more →OCGNOcugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
Read more →OCGNocgn-20231109xex991 Courageous Innovation Dedicated to Bringing Game-Changing Gene & Cell Therapies and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally November 2023 NASDAQ: OCGN Forward
OCGN announced significant advancements in its development of gene therapies and vaccines, particularly targeting inherited retinal diseases. The Phase 1/2 clinical trial for OCU400 has reported favorable safety results, with the Phase 3 trial for retinitis pigmentosa anticipated to start in early 2024. Additionally, upcoming vaccine candidates are being developed in collaboration with NIH/NIAID, positioning OCGN to potentially address public health challenges. The company emphasizes its commitment to innovation and improving patient access globally.
Read more →OCGNOcugen Provides Business Update with Third Quarter 2023 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and L
Ocugen, Inc. announced a business update alongside its Q3 2023 financial results, highlighting positive developments for its product candidates. Notably, OCU400 showed a favorable safety profile and significant efficacy in patients with genetic eye diseases, with 83% of subjects experiencing stabilization or improvement in visual acuity. The company's mucosal vaccine candidate, OCU500, was selected by NIAID for inclusion in upcoming clinical trials, showcasing a potential significant step forward. However, Ocugen reported a decrease in cash reserves and a mixed financial performance compared to the previous year.
Read more →OCGNOcugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
Read more →OCGNOcugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
Read more →OCGN▲ +10.3%on this news
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent
Ocugen's mucosal vaccine candidate OCU500 has been selected by the NIH's NIAID for early phase clinical trials, set to begin in early 2024. The vaccine will be tested via inhalation and nasal spray to assess the effectiveness of these delivery methods. The study aims to address whether an inhaled vaccine can elicit a stronger immune response compared to a nasal spray. This initiative is part of Project NextGen, which aims to develop advanced vaccines against COVID-19 and similar threats.
Read more →OCGNOcugen to Present at the 2023 Cell & Gene Meeting on the Mesa
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
Read more →OCGNOcugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
Read more →OCGNOcugen to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference
Ocugen to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference
Read more →OCGNOcugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
Read more →OCGNOcugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
Read more →OCGNOcugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Favorable
Ocugen, Inc. announced a positive clinical update on OCU400, a modifier gene therapy for Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA). The Phase 1/2 trial indicated favorable safety and efficacy outcomes, with initial results showing promise for vision stabilization in affected patients. The study involved a diverse group of subjects and the company is committed to continuing the trial to monitor long-term effects.
Read more →OCGNOcugen to Host Virtual Investor & Analyst Event on September 13, 2023
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
Read more →OCGN▼ -9%on this news
ocgn-20230822xex991 2 Improved visual outcomes and quality of life GENE X GENE M cell NR2E3 Delivery "Molecular reset" of health & survival gene networks cell Cell with normal function Restored retinal cell homeostasis O
The article discusses advancements in gene therapy, specifically through the NR2E3 delivery system, which aims to improve visual outcomes and overall quality of life for patients with retinal cell issues. The therapy achieves a 'molecular reset' of health and survival gene networks, potentially restoring normal function in retinal cells. This approach shows promise in enhancing ONL and photoreceptor survival in patients with mutated or nonfunctioning genes.
Read more →OCGNOcugen Provides Business Update with Second Quarter 2023 Financial Results Conference Call and Webcast Tomorrow at 8 30 a.m. ET Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic
Ocugen, Inc. reported its business update alongside second quarter 2023 financial results, announcing FDA clearance for IND applications for its gene therapies, OCU410 and OCU410ST. The company plans to initiate Phase 1/2 trials for these therapies by the end of 2023 and share updated clinical data for OCU400. Although financial results indicated an increase in net loss and operational expenses, Ocugen remains committed to enhancing its treatment pipeline for patients with serious diseases. A conference call will be held to discuss these developments and financial results further.
Read more →OCGNOcugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
Read more →OCGNOcugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
Read more →OCGNOcugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
Read more →OCGNocgn-20230605xex991 BIO Corporate Presentation Quan Vu, CFO/CBO BIO International 2023 2 2BIO Corporate Presentation Forward Looking Statements This presentation contains forward-looking statements within the meaning of
Ocugen, Inc. presented its corporate outlook for 2023, emphasizing its commitment to developing innovative gene and cell therapies as well as inhalation vaccines. The company highlighted positive preliminary results from its OCU400 Phase 1/2 trial aimed at treating inherited retinal diseases. Although Ocugen has received broad orphan drug designation from the FDA and EMA, the forward-looking statements acknowledge potential risks that could affect future developments and clinical trial outcomes. A Phase 3 trial for OCU400 is expected to be initiated by the end of 2023.
Read more →OCGNOcugen, Inc. Announces Business Advisory Board
Ocugen, Inc. Announces Business Advisory Board
Read more →OCGN▼ -35.1%on this news
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
Read more →OCGNOcugen to Present at BIO International Convention 2023
Ocugen to Present at BIO International Convention 2023
Read more →OCGNocgn-20230505xex991 Courageous Innovation May 2023 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 199
Ocugen, Inc. is progressing with its innovative gene therapy platform, particularly focusing on OCU400 for inherited retinal diseases. This therapy, currently in a Phase 1/2 trial, has shown a favorable safety profile alongside promising efficacy results related to visual function. The company has received broad orphan drug designations from both the FDA and EMA for conditions like retinitis pigmentosa and Leber congenital amaurosis, addressing significant unmet needs in these patient populations. However, Ocugen acknowledges potential risks and uncertainties in their forward-looking statements, which could affect future developments.
Read more →OCGNOcugen Provides Business Update with First Quarter 2023 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1 2 Trial of OCU400 fo
Ocugen, Inc. announced positive preliminary safety and efficacy results from the Phase 1/2 trial of its investigational therapy OCU400 for treating Retinitis Pigmentosa and Leber Congenital Amaurosis. The company also received Orphan Drug Designation from the FDA for OCU410ST, which targets ABCA4-associated retinopathies. Furthermore, Ocugen aims to advance its pipeline, including inhaled vaccines for COVID-19 and flu, despite facing challenges such as the FDA's hold on the trial for OCU200. Financial results show a decrease in cash reserves and a reported net loss per share.
Read more →OCGNOcugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
Read more →OCGNOcugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
Read more →OCGNOcugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
Read more →OCGN▼ -5.8%on this news· ran to -19% by day 3
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
Read more →OCGN▼ -6%on this news
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Fa
Ocugen announced positive preliminary results from a Phase 1/2 trial of its gene therapy product candidate OCU400, aimed at treating retinitis pigmentosa and Leber congenital amaurosis. The trial demonstrated a favorable safety profile, with over 70% of treated eyes showing significant improvement in visual mobility tests. Furthermore, the results support the potential of OCU400 as a gene-agnostic treatment for inherited retinal degeneration. The company plans to further analyze long-term data and may initiate Phase 3 trials in the near future.
Read more →OCGN▲ +7.4%on this newsshared move
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
Read more →OCGNOcugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
Read more →OCGNOcugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Read more →OCGNocgn-20230313xex991 Courageous Innovation March 2023 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1
Ocugen, Inc. recently presented its forward-looking statements and development pipeline aiming to address serious diseases. The company is pioneering gene therapies for inherited retinal diseases and has innovative biologics targeting eye diseases. Furthermore, Ocugen is developing vaccines and regenerative cell therapies, with notable clinical trials set to advance in 2023. The company highlights its commitment to market access and meaningful impact through these diverse therapeutic approaches.
Read more →OCGNOcugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
Read more →OCGN▼ -5.5%on this newsshared move
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
Read more →OCGNOcugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Completed retinitis pigmentosa patient enrollment in OCU400 Phase 1 2 clinical tr
Ocugen has provided a business update alongside their fourth quarter and full year 2022 financial results, highlighting significant clinical advancements. The company completed patient enrollment for the OCU400 Phase 1/2 trial focused on retinitis pigmentosa and submitted an IND application for OCU200. Despite achieving growth in their clinical pipeline and receiving FDA designations, Ocugen reported increased losses and rising R&D expenses. The company is gearing up for a Phase 3 clinical trial for NeoCart in 2024 and anticipates key milestones in 2023.
Read more →OCGNOcugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
Read more →OCGNOcugen to Present at Retinal Vascular Disease Drug Development Summit
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
Read more →OCGNOcugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Read more →OCGNocgn-20230206xex991 Courageous Innovation February 2023 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act o
Ocugen, Inc. provided an update on its pipeline and forward-looking statements regarding its ongoing research and development efforts. The company is focused on innovative treatments for severe diseases, particularly in the area of gene therapy and COVID-19 vaccines. Highlights from the pipeline include the COVAXIN vaccine for COVID-19, with emergency use authorization already in place for adults in Mexico and pending for younger populations. Furthermore, Ocugen is progressing with its gene therapies aimed at retinal diseases that currently lack approved treatments, while also preparing for upcoming phase 3 trials for its regenerative therapies.
Read more →OCGNOcugen Appoints Quan A. Vu as Chief Business Officer
Ocugen Appoints Quan A. Vu as Chief Business Officer
Read more →OCGNOcugen, Inc. to Present at 2023 BIO CEO & Investor Conference
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
Read more →OCGNocgn-20230109xex991 Courageous Innovation January 2023 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
Ocugen, Inc. has outlined its forward-looking strategies for January 2023, focusing on innovative therapies targeting serious diseases. The company is advancing projects such as its COVID-19 vaccine COVAXIN, which has received emergency use authorization in Mexico and is approaching FDA discussions for younger populations in the U.S. Ocugen is also working on modifier gene therapy and regenerative medicine to address inherited retinal diseases and detrimental effects on eye health. However, various risk factors related to clinical outcomes and regulatory processes could impact the company's forward momentum.
Read more →OCGNOcugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) in Phase 2 3 Immuno-bridging and Broadening Study Both Co-primary Endpoints Met Study met both co-primary endpoints with robust immu
Ocugen announced positive top-line results from a Phase 2/3 study of its COVID-19 vaccine candidate, COVAXIN (BBV152). The study met both co-primary endpoints demonstrating robust immune responses in participants. COVAXIN showed favorable safety profiles, with no serious adverse events reported. This data is positioned to bolster Ocugen's plans regarding COVAXIN's development in the U.S. amidst the ongoing need for diverse vaccine options.
Read more →OCGN▲ +5.5%on this news
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
Read more →OCGN▼ -8.8%on this newsshared move
Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis U.S. Food & Drug Administration (FDA) acknowledges the potential of OCU400 to treat rare inherited retinal
Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis U.S. Food & Drug Administration (FDA) acknowledges the potential of OCU400 to treat rare inherited retinal diseases Pa, December 15, 2022 (GLOBE NEWSWIRE) - Ocuge
Read more →OCGN▲ +5.4%on this newsshared move
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
Read more →OCGNOcugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
Read more →OCGNOcugen to Present at 3rd Annual Dry AMD Therapeutics Summit
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
Read more →OCGN▲ +7.2%on this news
ocgn-20221108xex991 Courageous Innovation November 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act o
Courageous Innovation November 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are based on the beliefs and assumptions of Ocugen, Inc. and on i
Read more →OCGN▲ +7.2%on this news
Ocugen Provides Business Update Third Quarter 2022 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1 2 OCU400 gene therapy clinical trial E
Ocugen Provides Business Update Third Quarter 2022 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1 2 OCU400 gene therapy clinical trial Expanded product pipeline with OCU500-Ocugen's mucosal COV
Read more →OCGNocgn-20221101xex991 Long-Term Outlook Shankar Musunuri, PhD, MBA Chairman of the Board, CEO & Co-founder R&D Day
Long-Term Outlook Shankar Musunuri, PhD, MBA Chairman of the Board, CEO & Co-founder R&D Day November 1, 2022 Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are
Read more →OCGN▼ -5.1%on this newsshared move
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
Read more →OCGNOcugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Read more →OCGNOcugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
Read more →OCGNOcugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
Read more →OCGN▼ -11.3%on this news
Ocugen, Inc. to Present at Chardan's 6th Annual Genetic Medicines Conference
Ocugen, Inc. to Present at Chardan's 6th Annual Genetic Medicines Conference
Read more →OCGN▲ +11.5%on this newsshared move
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
Read more →OCGN▼ -8.1%on this news· ran to -18% by day 3
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →OCGNOCUGEN ANNOUNCES PUBLICATION OF A COMPREHENSIVE REVIEW OF BBV152 IN FRONTIERS IN IMMUNOLOGY Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen
OCUGEN ANNOUNCES PUBLICATION OF A COMPREHENSIVE REVIEW OF BBV152 IN FRONTIERS IN IMMUNOLOGY Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen has North American commercialization rights for BBV152, c
Read more →OCGNOcugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Read more →OCGN▼ -7.9%on this newsshared move
Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference
Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference
Read more →OCGNOcugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer
Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer
Read more →OCGN▼ -6.7%on this news
ocgn-20220826xex991 Courageous Innovation August 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
Courageous Innovation August 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are based on the beliefs and assumptions of Ocugen, Inc. and on inf
Read more →OCGNocgn-20220817xex991 Courageous Innovation August 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
Courageous Innovation August 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are based on the beliefs and assumptions of Ocugen, Inc. and on inf
Read more →OCGNocgn-20220816xex991 Courageous Innovation August 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
Courageous Innovation August 2022 NASDAQ: OCGN Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are based on the beliefs and assumptions of Ocugen, Inc. and on inf
Read more →OCGN▲ +6%on this newsshared move
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Read more →OCGNOcugen Provides Business Update Second Quarter 2022 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Dosing patients in U.S. Phase 2 3 COVAXIN (BBV152) clinical trial Completed dosing of patients in Co
Ocugen Provides Business Update Second Quarter 2022 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Dosing patients in U.S. Phase 2 3 COVAXIN (BBV152) clinical trial Completed dosing of patients in Cohort 1 of OCU400 gene therapy product candidate Expandin
Read more →OCGNOcugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
Read more →OCGNOcugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
Read more →OCGNOcugen Named Among Philadelphia's '2022 Best Places to Work'
Ocugen Named Among Philadelphia's '2022 Best Places to Work'
Read more →OCGN▼ -8.8%on this newsshared move
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Read more →OCGN▼ -8.1%on this news· ran to -21% by day 3shared move
Ocugen, Inc. to Present at BIO International Convention 2022
Ocugen, Inc. to Present at BIO International Convention 2022
Read more →OCGN▼ -5%on this news
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition NeoCart (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help exp
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative MALVERN, Pa. - May 24, 2022
Read more →OCGNOcugen, Inc. to Present at H.C. Wainwright Global Investment Conference
Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
Read more →OCGNOcugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN (BBV152) Dosing to Resume Immediately MALVERN, Pa.
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN (BBV152) Dosing to Resume Immediately MALVERN, Pa. - May 23, 2022 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing
Read more →OCGN▼ -5.3%on this news· ran to -20% by day 3
Ocugen Provides Business Update and First Quarter 2022 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET OCU400 Phase 1 2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2
Ocugen Provides Business Update and First Quarter 2022 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET OCU400 Phase 1 2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after
Read more →OCGN▲ +6.8%on this news
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
Read more →OCGNOcugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Read more →OCGNOcugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Read more →OCGNocgn-20220420xex991 Courageous Innovation April 2022 NASDAQ: OCGN Forward Looking Statement 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 19
Courageous Innovation April 2022 NASDAQ: OCGN Forward Looking Statement 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use te
Read more →OCGNOcugen, Inc. to Present at NobleCon18
Ocugen, Inc. to Present at NobleCon18
Read more →OCGN▼ -5.8%on this newsshared move
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
Read more →OCGNOcugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN (BBV152) MALVERN, Pa.
Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN (BBV152) MALVERN, Pa., April 12, 2022 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines,
Read more →OCGNocgn-20220404xex991 Courageous Innovation March 2022 NASDAQ: OCGN Forward Looking Statement 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 19
Courageous Innovation March 2022 NASDAQ: OCGN Forward Looking Statement 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use te
Read more →OCGNOcugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Read more →OCGNOcugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
Read more →OCGNOcugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance
Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance
Read more →OCGN▼ -7.5%on this news
ocgn-20220311xex991 a biotech company focused on discovering, developing, and commercializing therapies that improve health and offer hope for people and global communities 2 Forward Looking Statement This presentation c
a biotech company focused on discovering, developing, and commercializing therapies that improve health and offer hope for people and global communities 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities
Read more →OCGN▲ +8.6%on this newsshared move
Ocugen, Inc. to Present at the 34th Annual ROTH Conference
Ocugen, Inc. to Present at the 34th Annual ROTH Conference
Read more →OCGN▼ -23.1%on this newsshared move
Ocugen Provides an Update on its COVAXIN Pediatric (2-18) Emergency Use Authorization (EUA) Request
Ocugen Provides an Update on its COVAXIN Pediatric (2-18) Emergency Use Authorization (EUA) Request MALVERN, Pa., Mar. 04, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing
Read more →OCGN▲ +5.4%on this news
Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET U.S. FDA lifts clinical hold on IND application for COVAXIN (BBV152), clearing th
Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET U.S. FDA lifts clinical hold on IND application for COVAXIN (BBV152), clearing the pathway for Phase 2 3 clinical trial in support of a BLA
Read more →OCGN▲ +22.3%on this newsshared move
ocgn-20220222xex991 Taking Science to New Heights for Patients February 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities L
Taking Science to New Heights for Patients February 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGN▲ +22.3%on this newsshared move
Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock
Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock
Read more →OCGNOcugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN (BBV152) MALVERN, Pa.
Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN (BBV152) MALVERN, Pa., February 18, 2022 - Ocugen, Inc. (NASDAQ OCGN), a clinical-stage biopharmaceutical company focused
Read more →OCGNOcugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update
Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update
Read more →OCGN▲ +7.1%on this newsshared move
Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options
Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options
Read more →OCGNocgn-20220214xex991 Taking Science to New Heights for Patients February 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities L
Taking Science to New Heights for Patients February 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGN▼ -6.2%on this news
ocgn-20220202xex991 Taking Science to New Heights for Patients February 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities L
Taking Science to New Heights for Patients February 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGN▼ -6.3%on this news· ran to +23% by day 3
Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada
Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada
Read more →OCGNOcugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety
Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety
Read more →OCGN▼ -7.9%on this newsshared move
Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →OCGNCOVAXIN (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-Cov-2 Booster dose of candidate vaccine, COVAXIN (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.5
COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-Cov-2 Booster dose of candidate vaccine, COVAXIN (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization
Read more →OCGN▲ +6.4%on this newsshared move
COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety Participants receiving a booster dose six months after second dose of COVAXIN saw significant increase ( 10-fold across Alpha,
COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety MALVERN, Pa., January 8, 2022 - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, annou
Read more →OCGNocgn-20220106xex991 Taking Science to New Heights for Patients January 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Li
Taking Science to New Heights for Patients January 2022 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We m
Read more →OCGNOcugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference
Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference
Read more →OCGN▲ +10.3%on this news
OCUGEN PARTNER, BHARAT BIOTECH, ANNOUNCES POSITIVE IMMUNOGENICITY AND SAFETY DATA FROM COVAXIN (BBV152), COVID-19 CANDIDATE VACCINE, IN CHILDREN 2 - 18 YEARS COVAXIN TM whole virus inactivated vaccine generated broad ant
OCUGEN PARTNER, BHARAT BIOTECH, ANNOUNCES POSITIVE IMMUNOGENICITY AND SAFETY DATA FROM COVAXIN (BBV152), COVID-19 CANDIDATE VACCINE, IN CHILDREN 2 - 18 YEARS MALVERN, Pa, December 30, 2021: Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, develo
Read more →OCGN▲ +12.7%on this newsshared move
New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
Read more →OCGN▲ +12.7%on this newsshared move
ocgn-20211215xex991 Taking Science to New Heights for Patients December 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities L
Taking Science to New Heights for Patients December 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGN▼ -6.3%on this news· ran to -20% by day 3
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1 2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Gene therapy candidate h
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1 2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Gene therapy candidate has potential to address a large number of Retinitis Pigment
Read more →OCGN▼ -9.2%on this news
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN (BBV152) MALVERN, Pa.
Ocugen, Inc. Provides an Update on its Investigational Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN MALVERN, Pa., November 26, 2021 - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discoverin
Read more →OCGNocgn-20211115xex991 Taking Science to New Heights for Patients November 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities L
Taking Science to New Heights for Patients November 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGN▼ -7.4%on this newsshared move
ocgn-20211109xex991 Taking Science to New Heights for Patients November 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities L
Taking Science to New Heights for Patients November 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGN▼ -7.4%on this newsshared move
Ocugen Provides Business Update and Third Quarter 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Emergency Use Authorization application filed with the U.S. FDA for the COVID-19 vaccine candidat
Ocugen Provides Business Update and Third Quarter 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Emergency Use Authorization application filed with the U.S. FDA for the COVID-19 vaccine candidate, COVAXIN (BBV152), for children aged 2 - 18 years Inves
Read more →OCGN▼ -6%on this newsshared move
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV- NR2E3) t o Treat Inherited Retinal Degeneratio
Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration Modifier gene therapy platform has potential to treat multiple retin
Read more →OCGNOcugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN (BBV152) for Children Ages 2-18 Years COVAXIN (BBV152) was recently awarded Emergency Us
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN (BBV152) for Children Ages 2-18 Years MALVERN, Pa., - November 5, 2021 - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on disc
Read more →OCGN▲ +12.1%on this news· ran to -27% by day 3shared move
Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update
Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update
Read more →OCGN▲ +12.1%on this news· ran to -27% by day 3shared move
ocgn-20211102xex991 Taking Science to New Heights for Patients November 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities L
Taking Science to New Heights for Patients November 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGN▲ +5%on this news· ran to +53% by day 3
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN (BBV152) The Phase 3 study is designed to bridge
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN (BBV152) The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in
Read more →OCGNOcugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference
Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference
Read more →OCGNOcugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference
Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference
Read more →OCGNocgn-20210908xex991 Taking Science to New Heights for Patients September 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities
Taking Science to New Heights for Patients September 2021 NASDAQ: OCGN 1 2 Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We
Read more →OCGNOcugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
Read more →OCGNOcugen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses of $100,000 are encouraged to contact the firm before August 17, 2021; click here to submit trade information LOS ANGELES, Aug. 17, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Ocug
Read more →OCGNOcugen Provides Business Update and Second Quarter 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated U.S. FDA t
Ocugen Provides Business Update and Second Quarter 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated U.S. FDA talks continue Multiple milestones achieved across regulat
Read more →OCGNOcugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET
Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET
Read more →OCGNOcugen, Inc. Announces Initiation of Rolling Submission to Health Canada for
Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN MALVERN, Pa, July 15, 2021 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness dise
Read more →OCGNocgn-20210709xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: July 2021 1 2021 Ocugen. All Rights Reserved. Forward
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: July 2021 6 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Licensed from Bharat Biotech (BBIL) for the US and Canadian Markets 1
Read more →OCGNocgn-20210720xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: July 2021 1 2021 Ocugen. All Rights Reserved. Forward
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: July 2021 6 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Licensed from Bharat Biotech (BBIL) for the US and Canadian Markets 1
Read more →OCGNOcugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Efficacy analysis demonstrates COVAXIN to be 93.4% protective against severe
Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease MALVERN, PA, and HYDERABAD, INDIA, July 2, 2021 - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, de
Read more →OCGNOcugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications
Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications
Read more →OCGNOcugen Inc. Set to Join Russell 3000® Index
Ocugen Inc. Set to Join Russell 3000® Index
Read more →OCGNOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
Read more →OCGNOcugen, Inc. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, June 11, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investor
Read more →OCGNOcugen Inc. Announces Michael Shine as Senior Vice President, Commercial
Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial
Read more →OCGNOcugen to pursue a BLA path in the US for its COVID-19 vaccine candidate Company intends to work with the FDA towards filing a Biologics License Application (BLA) in the US Company to engage with Health Canada to seek au
Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate Company intends to work with the FDA towards filing a Biologics License Application (BLA) in the US Company to engage with Health Canada to seek authorization under Interim Order for use in Canada MALVERN
Read more →OCGNOcugen Expands COVAXIN™ Commercialization Rights to Include Canada
Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada
Read more →OCGNOcugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™
Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™
Read more →OCGNocgn-20210519xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: May 2021 2 2021 Ocugen. All Rights Reserved. Forward
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: May 2021 7 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Licensed from Bharat Biotech (BBIL) for the US Market 20 Ocugen's Modi
Read more →OCGNocgn-20210507xex991cd Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: May 2021 2 2021 Ocugen. All Rights Reserved. Forwar
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: May 2021 7 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Licensed from Bharat Biotech (BBIL) for the US Market 20 Ocugen's Modi
Read more →OCGNOcugen Provides Business Update and First Quarter 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization) Ma
Ocugen Provides Business Update and First Quarter 2021 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization) Master File submitted for U.S. Food and Drug Administration
Read more →OCGNOcugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
Read more →OCGNOcugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update
Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update
Read more →OCGNOcugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2
Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2
Read more →OCGNOcugen Inc. Announces Closing of $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Ocugen Inc. Announces Closing of $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Read more →OCGNOcugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Read more →OCGNOcugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization Primary efficacy in the second interim analys
Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization MALVERN, PA, April 21, 2021 - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on disc
Read more →OCGNOcugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain
Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain
Read more →OCGNocgn-20210331xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: March 2021 2 2021 Ocugen. All Rights Reserved. Forwar
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: March 2021 7 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Licensed from Bharat Biotech (BBIL) for the US Market 15 Ocugen's Mo
Read more →OCGNOcugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development
Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development
Read more →OCGNOcugen Provides Business Update and Full Year 2020 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET COVID-19 vaccine candidate, COVAXIN , demonstrates efficacy of 81% in Phase 3 interim results Emergen
Ocugen Provides Business Update and Full Year 2020 Financial Results Conference Call and Webcast Today at 8 30 a.m. ET COVID-19 vaccine candidate, COVAXIN , demonstrates efficacy of 81% in Phase 3 interim results Emergency Use Authorization pathway with U.S. regulatory authori
Read more →OCGNOcugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update
Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update
Read more →OCGNOcugen Inc. to Present at Upcoming March Investor Conferences
Ocugen Inc. to Present at Upcoming March Investor Conferences
Read more →OCGNocgn-20200305xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: March 2021 1 2021 Ocugen. All Rights Reserved. Forwar
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: March 2021 6 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Licensed from Bharat Biotech (BBIL) for the US Market 14 Ocugen's Mo
Read more →OCGNOcugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% Data from 25,800 participants in Phase 3 trial in India, received vaccine or placeb
COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% Malvern, PA-March 03, 2021 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commerc
Read more →OCGNEuropean Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis Malvern, PA
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis Malvern, PA-February 23, 2021 (GLOBE NEWSWIRE) - Ocugen, Inc., (NASDAQ OCGN), a biopha
Read more →OCGNOcugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
Read more →OCGNOcugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Read more →OCGNOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market
Read more →OCGNocgn-20200205xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: February 2021 1 2021 Ocugen. All Rights Reserved. For
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to Save Lives from COVID-19 NASDAQ: OCGN Corporate Deck: February 2021 6 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Licensed from Bharat Biotech (BBIL) for the US Market 14 Ocugen's
Read more →OCGNOcugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021
Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021
Read more →OCGNOcugen Inc. Regains Compliance with Nasdaq Bid Price Rule MALVERN, PA
Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule MALVERN, PA, January 8, 2021 (GLOBE NEWSWIRE)- Ocugen, Inc. (NASDAQ OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vac
Read more →OCGNOcugen Inc. to Present at CTIC, HC Wainwright and Noble Capital Investor Conferences
Ocugen Inc. to Present at CTIC, HC Wainwright and Noble Capital Investor Conferences
Read more →OCGNocgn-20210105xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to fight COVID-19 NASDAQ: OCGN Corporate Deck: January 2021 1 2021 Ocugen. All Rights Reserved. Forward Lookin
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases and Develop a Vaccine to fight COVID-19 NASDAQ: OCGN Corporate Deck: January 2021 6 COVAXIN Whole-Virion Inactivated COVID-19 Vaccine Being Co-Developed for the US Market Ocugen's Modifier Gene Therapy Platform
Read more →OCGNOcugen Establishes Vaccine Scientific Advisory Board
Ocugen Establishes Vaccine Scientific Advisory Board
Read more →OCGNOcugen and Bharat Biotech TO Co-DEVELOP COVAXIN , a Whole-Virion Inactivated COVID-19 Vaccine, for the US market Companies will co-develop inactivated vaccine candidate, COVAXIN , to prevent COVID-19 infection in the US
and Bharat Biotech TO Co-DEVELOP COVAXIN , a Whole-Virion Inactivated COVID-19 Vaccine, for the US market Companies will co-develop inactivated vaccine candidate, COVAXIN , to prevent COVID-19 infection in the US Builds upon the promising safety and immunogenicity data in the
Read more →OCGNOcugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares
Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares
Read more →OCGNOcugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders
Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders
Read more →OCGNLeading Independent Proxy Firms ISS and Glass Lewis Recommend Ocugen Stockholders Vote "FOR" Reverse Stock Split and Authorized Shares Amendment Proposals
Leading Independent Proxy Firms ISS and Glass Lewis Recommend Ocugen Stockholders Vote "FOR" Reverse Stock Split and Authorized Shares Amendment Proposals
Read more →OCGNCEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy's Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies
CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy's Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies
Read more →OCGNocgn-20201106xex991cd Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Nov 2020 Forward Looking Statement This presentation contains forward-looking statements that involve
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Nov 2020 Ocugen's Modifier Gene Therapy Platform Breakthrough Technology Designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 5
Read more →OCGNOcugen Provides Business Update and Third Quarter 2020 Financial Results First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021 MALVERN, PA
Ocugen Provides Business Update and Third Quarter 2020 Financial Results First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021 MALVERN, PA, November 6, 2020 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ OCGN), a biopharmaceutical company focused on discovering, dev
Read more →OCGNOcugen to Present at the GCFF Virtual Conference - Diversified Investing Strategies
Ocugen to Present at the GCFF Virtual Conference - Diversified Investing Strategies
Read more →OCGNCEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference
CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference
Read more →OCGNocgn-20201020xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Oct 2020 Forward Looking Statement This presentation contains forward-looking statements that involve s
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Oct 2020 Ocugen's Modifier Gene Therapy Platform Breakthrough Technology Designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 5
Read more →OCGNCantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen
Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen
Read more →OCGNOcugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200 Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned MALVERN, PA
Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200 Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned MALVERN, PA, October 6, 2020 (GLOBE NEWSWIRE) - Ocugen, Inc., (NASDAQ OCGN), a biopharmaceutical company focused on discovering, developing,
Read more →OCGNOcugen to Participate in a Virtual Fireside Chat at the Chardan Genetic Medicines Conference
Ocugen to Participate in a Virtual Fireside Chat at the Chardan Genetic Medicines Conference
Read more →OCGNOcugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Ocugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Read more →OCGNOcugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Ocugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Read more →OCGNOcugen to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Ocugen to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Read more →OCGNOcugen to Present at the LD 500 Virtual Investor Conference
Ocugen to Present at the LD 500 Virtual Investor Conference
Read more →OCGNocgn-20200817xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Aug 2020 Forward Looking Statement This presentation contains forward-looking statements that involve s
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Aug 2020 Ocugen's Modifier Gene Therapy Platform Breakthrough Technology designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 5
Read more →OCGNOcugen Provides Business Update and Second Quarter 2020 Financial Results Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8 30 a.m.
Ocugen Provides Business Update and Second Quarter 2020 Financial Results Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8 30 a.m. ET MALVERN, PA, August 14, 2020 (GLOBE NEWSWIRE) - Ocugen, Inc. (NA
Read more →OCGNOcugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV- NR2E3 ) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Disease
Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases Fourth orphan drug designation for the same product, OCU400
Read more →OCGNOcugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET
Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET
Read more →OCGNocgn-20200804xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Aug 2020 Forward Looking Statement This presentation contains forward-looking statements that involve s
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Aug 2020 Ocugen's Modifier Gene Therapy Platform Breakthrough Technology designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 5
Read more →OCGNOcugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease Third orphan drug designation for the same product, OCU400, is uni
Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease Third orphan drug designation for the same product, OCU400, is unique in Ophthalmology gene therapy and demonstrates its pote
Read more →OCGNOcugen to Present at World Orphan Drug Congress USA 2020 Conference
Ocugen to Present at World Orphan Drug Congress USA 2020 Conference
Read more →OCGNocgn-20200716xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: July 2020 Forward Looking Statement This presentation contains forward-looking statements that involve
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: July 2020 Ocugen's Modifier Gene Therapy Platform Breakthrough Technology designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 6
Read more →OCGNocgn-20200603xex991 Our Mission is to develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck Forward Looking Statement This presentation contains forward-looking statements that involve substantial
Our Mission is to develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck Breakthrough Modifier Gene Therapy Platform Addressing Multiple Diseases with One Product 6 OCU200: Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Wet AMD Novel Biologic Offe
Read more →OCGNOcugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board
Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board
Read more →OCGNOcugen to Discontinue Phase 3 oGVHD Trial Breakthrough Modifier Gene Therapy platform continues to advance towards clinic MALVERN, PA
Ocugen to Discontinue Phase 3 oGVHD Trial Breakthrough Modifier Gene Therapy platform continues to advance towards clinic MALVERN, PA, June 1, 2020 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ OCGN), a clinical-stage company focused on discovering, developing and commercializing tra
Read more →OCGNOcugen to Discontinue Phase 3 oGVHD Trial
Ocugen to Discontinue Phase 3 oGVHD Trial
Read more →OCGNOcugen Provides Business Update and First Quarter 2020 Financial Results 100% of planned enrollment completed in Phase 3 oGVHD study topline results anticipated by end of 2020 MALVERN, PA
Ocugen Provides Business Update and First Quarter 2020 Financial Results 100% of planned enrollment completed in Phase 3 oGVHD study topline results anticipated by end of 2020 MALVERN, PA, May 8, 2020 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ OCGN), a clinical-stage company focus
Read more →OCGNOcugen Announces Completion of Warrant Exchange
Ocugen Announces Completion of Warrant Exchange
Read more →OCGNOcugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors
Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors
Read more →OCGNOcugen Provides Business Update and Full Year 2019 Financial Results
Ocugen Provides Business Update and Full Year 2019 Financial Results
Read more →OCGNOcugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update
Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update
Read more →OCGNNature Gene Therapy Publishes Preclinical Data of Ocugen's OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)
Nature Gene Therapy Publishes Preclinical Data of Ocugen's OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)
Read more →OCGNOcugen to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference
Ocugen to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference
Read more →OCGNOcugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD Topline data anticipated in second half of 2020 MALVERN, PA
Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD Topline data anticipated in second half MALVERN, PA, December 9, 2019 (GLOBE NEWSWIRE) - Ocugen, Inc., (NASDAQ: OCGN), ), a clinical-stage biopharmaceutical company focused on discovering,
Read more →OCGNForward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation,
Developing Innovative Therapies to Address Rare Diseases and Underserved NASDAQ: OCGN Eye Corporate Deck Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of hi
Read more →OCGNOcugen Provides Business Update and Third Quarter 2019 Financial Highlights
Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights
Read more →OCGNOcugen Announces Warrant Restructuring Reduced Series C warrant shares to 20 million from 50 million MALVERN, PA, November 6 , 2019 (GLOBE NEWSWIRE) - Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical comp
Ocugen Announces Warrant Restructuring Reduced Series C warrant shares to 20 million from 50 million MALVERN, PA, November 6, 2019 (GLOBE NEWSWIRE) - Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing
Read more →OCGNOcugen Announces Warrant Restructuring
Ocugen Announces Warrant Restructuring
Read more →OCGNOcugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards
Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards
Read more →OCGNOcugen Provides Business Update and Third Quarter 2019 Financial Highlights Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, PA, November 8 , 2019 (GLOBE NEWSWIRE) - Ocugen, Inc., (NASDAQ: OCGN), a clinical sta
Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, PA, November 8, 2019 (GLOBE NEWSWIRE) - Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, develo
Read more →OCGNOcugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
Read more →OCGNOcugen Appoints Jessica Crespo, CPA, as Controller
Ocugen Appoints Jessica Crespo, CPA, as Controller
Read more →OCGNOcugen Announces Share Repurchase Program
Ocugen Announces Share Repurchase Program
Read more →OCGNOcugen Announces Amendment to Asset Purchase Agreement
Ocugen Announces Amendment to Asset Purchase Agreement
Read more →OCGNOcugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer
Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer
Read more →OCGNOcugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics MALVERN, PA, September 30 , 2019 (BUSINESSWIRE) - Ocuge
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics MALVERN, PA, September 30, 2019 (BUSINESSWIRE) - Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical
Read more →OCGNOcugen to Present at Three Upcoming Conferences
Ocugen to Present at Three Upcoming Conferences
Read more →OCGNto the Form 8-K of Ocugen, Inc. (previously known as Histogeniccs) filed with the Securities and Exchange Commission (the SEC ) on
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2019 and for the three and six month periods ended June 30, 2019 and 2018 On September 27, 2019, Histogenics Corporation ( Histogenics ) completed its business combination with
Read more →OCGNDeveloping Innovative Therapies to Address Rare Diseases and Underserved NASDAQ: OCGN Eye Corporate Deck Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and
Developing Innovative Therapies to Address Rare Diseases and Underserved NASDAQ: OCGN Eye Corporate Deck Orphan us oGVHD OCU300 NR2f3 Mutation-Associated Retinal Degeneration Orphan us CfP290 Mutation-Associated Retinal Degeneration Orphan us OCU400 NIVI-?-AAV Rhodopsin Mutation
Read more →OCGNHistogenics Announces Approval of Merger by Stockholders at Special Meeting
Histogenics Announces Approval of Merger by Stockholders at Special Meeting BOSTON, Mass. September 26, 2019 Histogenics Corporation (Nasdaq: HSGX) (the Company or Histogenics ) today announced that all proposals related to its proposed merger with Ocugen, Inc. ( Ocugen ) were
Read more →OCGNOcugen Granted FDA Orphan Drug Designation for OCU400 (NR2E3) Gene Therapy for the Treatment of CEP290 Mutation Associated Retinal Disease
Ocugen Granted FDA Orphan Drug Designation for OCU400 (NR2E3) Gene Therapy for the Treatment of CEP290 Mutation Associated Retinal Disease
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES ADJOURNMENT OF ITS SPECIAL MEETING TO THURSDAY, SEPTEMBER 26, 2019
HISTOGENICS CORPORATION ANNOUNCES ADJOURNMENT OF ITS SPECIAL MEETING TO THURSDAY, SEPTEMBER 26, 2019 BOSTON, Mass. September 12, 2019 Histogenics Corporation (Nasdaq: HSGX) (the Company or Histogenics ) today announced that it convened and then adjourned, without conducting an
Read more →OCGNHISTOGENICS
HISTOGENICS CORPORATION ANNOUNCES INTENT TO CONVENE AND ADJOURN ITS SPECIAL MEETING BOSTON, Mass. September 11, 2019 Histogenics Corporation (Nasdaq: HSGX) (the Company or Histogenics ) today announced that it intends to convene and then adjourn, without conducting any busines
Read more →OCGNHistogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics Conference call to be held today at 8:30 a.m. Easter
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics Conference call to be held today at 8:30 a.m. Eastern Time BOSTON, Mass. and MALVERN, Penn. April 8, 2019 His
Read more →OCGNOcugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease
Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease
Read more →OCGNHISTOGENICS AND FDA CONCLUDE DISCUSSIONS REGARDING NEOCART PHASE 3 CLINICAL TRIAL DATA AND REGULATORY PATHWAY Histogenics to Discontinue Development of NeoCart and Explore Strategic Alternatives
HISTOGENICS AND FDA CONCLUDE DISCUSSIONS REGARDING PHASE 3 CLINICAL TRIAL DATA AND REGULATORY PATHWAY Histogenics to Discontinue Development of NeoCart and Explore Strategic Alternatives WALTHAM, Mass., December 21, 2018 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (
Read more →OCGNHISTOGENICS AND FDA CONTINUE TO DISCUSS NEOCART PHASE 3
HISTOGENICS AND FDA CONTINUE TO DISCUSS NEOCART PHASE 3 CLINICAL TRIAL DATA AND POTENTIAL REGULATORY PATHWAY WALTHAM, Mass., November 29, 2018 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS Histogenics and FDA Continue Discussions on NeoCart Phase 3 Data and Potential BLA Submission October 2018 Financing Expected to Provid
HISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS Histogenics and FDA Continue Discussions on NeoCart Phase 3 Data and Potential BLA Submission October 2018 Financing Expected to Provide Funding Into Middle of 2019 Histogenics to Host Confe
Read more →OCGNHISTOGENICS AND FDA TO CONTINUE DISCUSSIONS ON NEOCART PHASE 3
HISTOGENICS AND FDA TO CONTINUE DISCUSSIONS ON NEOCART PHASE 3 CLINICAL TRIAL DATA AND POTENTIAL REGULATORY PATHWAY WALTHAM, Mass., November 1, 2018 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies
Read more →OCGNOcugen to Highlight Phase 2 Clinical Data for OCU310 at AAO 2018
Ocugen to Highlight Phase 2 Clinical Data for OCU310 at AAO 2018
Read more →OCGNOcugen Initiates Phase 3 Clinical Trial of OCU310 for Dry Eye Disease
Ocugen Initiates Phase 3 Clinical Trial of OCU310 for Dry Eye Disease
Read more →OCGNHISTOGENICS TO MEET WITH FDA TO DISCUSS NEOCART PHASE 3
HISTOGENICS TO MEET WITH FDA TO DISCUSS NEOCART PHASE 3 CLINICAL TRIAL DATA AND POTENTIAL REGULATORY WALTHAM, Mass., September 26, 2018 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offe
Read more →OCGNOcugen to Present at Two Upcoming Investor Conferences
Ocugen to Present at Two Upcoming Investor Conferences
Read more →OCGNDisclaimer Regarding Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements." All statements, other than statements of historical facts, included in this
NeoCart Phase 3 Clinical Trial Results Call September 5, 2018 Exhibit 99.1 Disclaimer Regarding Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements." All statements, other than statements of historical facts,
Read more →OCGNOcugen Appoints James G. Murphy, CPA, as Chief Financial Officer
Ocugen Appoints James G. Murphy, CPA, as Chief Financial Officer
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS Top-line Superiority Data from NeoCart Phase 3 Clinical Trial on Track for Third Quarter of 2018 Initiation of Phase 3 Clinical Trial
HISTOGENICS CORPORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS Top-line Superiority Data from NeoCart Phase 3 Clinical Trial on Track for Third Quarter of 2018 Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 Expansion of Management Team in Pr
Read more →OCGNOcugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease
Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease
Read more →OCGNHistogenics Restorative Cell Therapies for Active Living Investor Day
Agenda Time Topic Speaker Duration 8:15 am Introductions and corporate overview Adam Gridley 15 Minutes 8:30 am Physician Panel - The Clinicians Perspective Dr. DerykJones Dr. Dean Taylor Moderator: Adam Gridley 40 Minutes 9:10 am Care Pathway and Patient Impact - A Patient s Pe
Read more →OCGNOcugen to Present at the 2018 BIO International Convention
Ocugen to Present at the 2018 BIO International Convention
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS Top-line Superiority Data from NeoCart Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third
HISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS Top-line Superiority Data from NeoCart Phase 3 Clinical Trial and Potential Biologics License Submission on Track for Third Quarter of 2018 Initiation of Phase 3 Clinical Trial in Japan Expe
Read more →OCGNOcugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018
Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018
Read more →OCGNOcugen to Highlight Potential Efficacy of its Proprietary Nanoemulsion Technology at ARVO 2018
Ocugen to Highlight Potential Efficacy of its Proprietary Nanoemulsion Technology at ARVO 2018
Read more →OCGNOcugen Announces CEO Dr. Shankar Musunuri Named a Finalist for Ernst & Young Entrepreneur Of The Year® 2018 Award
Ocugen Announces CEO Dr. Shankar Musunuri Named a Finalist for Ernst & Young Entrepreneur Of The Year® 2018 Award
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES THE APPOINTMENT OF SUSAN WASHER TO ITS BOARD OF DIRECTORS Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, MA
HISTOGENICS CORPORATION ANNOUNCES THE APPOINTMENT OF SUSAN WASHER TO ITS BOARD OF DIRECTORS Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, MA, April 18, 2018 /PRNewswire/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a
Read more →OCGNOcugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease
Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017 NeoCart Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Re
HISTOGENICS CORPORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017 NeoCart Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensi
Read more →OCGNOcugen to Present at the Oppenheimer 28th Annual Healthcare Conference
Ocugen to Present at the Oppenheimer 28th Annual Healthcare Conference
Read more →OCGNOcugen to Present at 2018 BIO CEO & Investor Conference
Ocugen to Present at 2018 BIO CEO & Investor Conference
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN REGISTERED DIRECT OFFERING OF 2,340,430
HISTOGENICS CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN REGISTERED DIRECT OFFERING OF 2,340,430 SHARES OF COMMON STOCK WALTHAM, Mass., January 22, 2018 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell ther
Read more →OCGNHISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET Transaction Terms Include a $10 Million Up-front Payment with a Potenti
HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET Transaction Terms Include a $10 Million Up-front Payment with a Potential of $87 Million in Total Milestones, and Tiered Royalti
Read more →OCGNOcugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform
Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2017 FINANCIAL AND OPERATING RESULTS Top-line, 1-year Superiority Data for NeoCart Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track
HISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2017 FINANCIAL AND OPERATING RESULTS Top-line, 1-year Superiority Data for NeoCart Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 Company to Host Conference Cal
Read more →OCGNHISTOGENICS CORPORATION PROMOTES STEPHEN KENNEDY TO EXECUTIVE VICE PRESIDENT &
HISTOGENICS CORPORATION PROMOTES STEPHEN KENNEDY TO EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER WALTHAM, Mass., October 12, 2017 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leading cell therapy company focused on developing and commercializi
Read more →OCGNOcugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease
Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease
Read more →OCGNOcugen Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
Ocugen Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES SECOND QUARTER 2017 FINANCIAL AND OPERATING RESULTS Completed Enrollment in NeoCart Phase 3 Clinical Trial Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 Define
HISTOGENICS CORPORATION ANNOUNCES SECOND QUARTER 2017 FINANCIAL AND OPERATING RESULTS Completed Enrollment in NeoCart Phase 3 Clinical Trial Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 Defined Regulatory Pathway with Japan Pharmaceuticals and Medi
Read more →OCGNOcugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Read more →OCGNHISTOGENICS COMPLETES ENROLLMENT FOR PHASE 3 CLINICAL TRIAL OF NEOCART TO TREAT KNEE CARTILAGE DAMAGE On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 Novel Tissue Implant
HISTOGENICS COMPLETES ENROLLMENT FOR PHASE 3 CLINICAL TRIAL OF NEOCART TO TREAT KNEE CARTILAGE DAMAGE On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 Novel Tissue Implant Potentially Accelerates Recovery and Reduces Pain throug
Read more →OCGNOcugen Makes Strategic Appointments to Management Team
Ocugen Makes Strategic Appointments to Management Team
Read more →OCGNOcugen Closes $7.5 Million Series B Financing
Ocugen Closes $7.5 Million Series B Financing
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2017 FINANCIAL AND OPERATING RESULTS NeoCart Phase 3 Clinical Trial Enrollment Near Completion NeoCart Approval Pathway in Japan Defined After Successful Conclusion of Disc
HISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2017 FINANCIAL AND OPERATING RESULTS NeoCart Phase 3 Clinical Trial Enrollment Near Completion NeoCart Approval Pathway in Japan Defined After Successful Conclusion of Discussions with the Japan Pharmaceuticals and Medical Devic
Read more →OCGNOcugen Expands Global Patent Portfolio for OCU200
Ocugen Expands Global Patent Portfolio for OCU200
Read more →OCGNHISTOGENICS ANNOUNCES AGREEMENT WITH THE JAPAN PHARMACEUTICALS AND MEDICAL DEVICES AGENCY REGARDING JAPANESE REGULATORY PATHWAY FOR NEOCART Long history and significant US data package may enable full Marketing and Manuf
HISTOGENICS ANNOUNCES AGREEMENT WITH THE JAPAN PHARMACEUTICALS AND MEDICAL DEVICES AGENCY REGARDING JAPANESE REGULATORY PATHWAY FOR Long history and significant US data package may enable full Marketing and Manufacturing Authorization of NeoCart subject to successful completio
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2016 NeoCart Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017
HISTOGENICS CORPORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2016 NeoCart Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 Strong Performance in all Areas of the Business in 2016
Read more →OCGNOcugen Closes $6 Million in Series A Funding
Ocugen Closes $6 Million in Series A Funding
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2016 FINANCIAL AND OPERATING RESULTS - NeoCart Phase 3 Clinical Trial More than 75% Enrolled - - Enrollment On-Track to Complete by End of Second Quarter of 2017 - - Third
HISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2016 FINANCIAL AND OPERATING RESULTS - NeoCart Phase 3 Clinical Trial More than 75% Enrolled - - Enrollment On-Track to Complete by End of Second Quarter of 2017 - - Third Quarter Financing Expected to Fund Company to Phase 3 Da
Read more →OCGNHISTOGENICS CORPORATION PROVIDES NEOCART PHASE 3 CLINICAL TRIAL ENROLLMENT UPDATE - 75% of Patients Enrolled in NeoCart Phase 3 Clinical Trial
HISTOGENICS CORPORATION PROVIDES NEOCART PHASE 3 CLINICAL TRIAL ENROLLMENT UPDATE - 75% of Patients Enrolled in NeoCart Phase 3 Clinical Trial - WALTHAM, Mass., October 24, 2016 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine comp
Read more →OCGNHISTOGENICS CORPORATION CLOSES $30.0
HISTOGENICS CORPORATION CLOSES $30.0 MILLION PRIVATE PLACEMENT WALTHAM, Mass., September 29, 2016 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal spa
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES $30.0
HISTOGENICS CORPORATION ANNOUNCES $30.0 MILLION PRIVATE PLACEMENT WALTHAM, Mass., September 16, 2016 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES SECOND QUARTER 2016 FINANCIAL AND OPERATING RESULTS - NeoCart Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Increasing Year-End 2
HISTOGENICS CORPORATION ANNOUNCES SECOND QUARTER 2016 FINANCIAL AND OPERATING RESULTS - NeoCart Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Increasing Year-End 2016 Enrollment Guidance to 190 to 200 patients - - Comp
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2016 FINANCIAL AND OPERATING RESULTS - NeoCart Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Company to Host Confer
HISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2016 FINANCIAL AND OPERATING RESULTS - NeoCart Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017 - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM,
Read more →OCGNHISTOGENICS CORPORATION ACQUIRES NEOCART DEVELOPMENT AND COMMERCIALIZATION RIGHTS FOR JAPANESE MARKET - Developing Plans to Re-Engage with Japanese Regulatory Authorities and Seek Development and Commercialization Partne
HISTOGENICS CORPORATION ACQUIRES NEOCART COMMERCIALIZATION RIGHTS FOR JAPANESE MARKET - Developing Plans to Re-Engage with Japanese Regulatory Authorities and Seek Development and Commercialization Partners in Japan - WALTHAM, Mass., May 10, 2016 /GLOBE NEWSWIRE/ Histogenics
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2015 - NeoCart Phase 3 Clinical Trial More Than 50% Enrolled and on Track for Full Enrollment by End of
HISTOGENICS CORPORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2015 - NeoCart Phase 3 Clinical Trial More Than 50% Enrolled and on Track for Full by End of Second Quarter of 2017 - - Company to Host Conference Call and Web
Read more →OCGNHISTOGENICS CORPORATION PROVIDES NEOCART PHASE 3 CLINICAL TRIAL ENROLLMENT UPDATE - 50% of Patients Enrolled in NeoCart Phase 3 Clinical Trial
HISTOGENICS CORPORATION PROVIDES NEOCART PHASE 3 CLINICAL TRIAL ENROLLMENT UPDATE - 50% of Patients Enrolled in NeoCart Phase 3 Clinical Trial - WALTHAM, Mass., February 2, 2016 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine comp
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES AMENDMENT TO NEOCART PHASE 3 CLINICAL TRIAL ENROLLMENT CRITERIA - Company and FDA Agree on Changes to Study Protocol Allowing for Modification of Patient Inclusion/Exclusion Criteria
HISTOGENICS CORPORATION ANNOUNCES AMENDMENT TO NEOCART PHASE 3 CLINICAL TRIAL ENROLLMENT CRITERIA - Company and FDA Agree on Changes to Study Protocol Allowing for Modification of Patient Inclusion/Exclusion Criteria - WALTHAM, Mass., December 21, 2015 /GLOBE NEWSWIRE/ Histogen
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2015 FINANCIAL AND OPERATING RESULTS - Completion of Enrollment of NeoCart Phase 3 Trial Now Expected in Second Quarter of 2017 - - Company to Host Conference Call and Webc
HISTOGENICS CORPORATION ANNOUNCES THIRD QUARTER 2015 FINANCIAL AND OPERATING RESULTS - Completion of Enrollment of NeoCart Phase 3 Trial Now Expected in Second Quarter of 2017 - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EST - WALTHAM, Mass., November 12
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES SECOND QUARTER 2015 FINANCIAL AND OPERATING RESULTS - Continued Progress on NeoCart Phase 3 Trial and 2015 Business Objectives - - Company to Host Conference Call and Webcast Today at 8:
HISTOGENICS CORPORATION ANNOUNCES SECOND QUARTER 2015 FINANCIAL AND OPERATING RESULTS - Continued Progress on NeoCart Phase 3 Trial and 2015 Business Objectives - - Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., August 12, 2015 /GLOBE NEW
Read more →OCGNHistogenics Corporation Announces Appointment of Stephen Kennedy to Chief Technology Officer Experienced Scientific and Technical Operations Executive Promoted to Lead Product Development and Manufacturing Operations
Histogenics Corporation Announces Appointment of Stephen Kennedy to Chief Technology Officer Experienced Scientific and Technical Operations Executive Promoted to Lead Product Development and Manufacturing Operations WALTHAM, Mass., July 30, 2015 /PRNewswire/ Histogenics Corpor
Read more →OCGNHistogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer Globally Recognized Thought Leader in Cell Therapy, Cartilage Repair and Orthopedics Joins Executive Team
Histogenics Corporation Announces Dr. Gloria Matthews as Chief Medical Officer Globally Recognized Thought Leader in Cell Therapy, Cartilage Repair and Orthopedics Joins Executive Team WALTHAM, Mass., July 15, 2015 /PRNewswire/ Histogenics Corporation (Histogenics) (Nasdaq: HSG
Read more →OCGNForward - Looking Statements Various statements in this release are forward-looking statements under the securities laws. Words such as, but not limited to, anticipate, believe, can, could, expect, estimate, design, goal
Histogenics Corporation Announces Appointment of New Chief Financial Officer Experienced Financial and Investment Banking Executive Jonathan Lieber to Join Executive Team WALTHAM, Mass., June 22, 2015 /PRNewswire/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenera
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2015
HISTOGENICS CORPORATION ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS WALTHAM, Mass., May 14, 2015 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal s
Read more →OCGNHISTOGENICS CORPORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014
HISTOGENICS CORPORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS WALTHAM, Mass., February 26, 2015 /GLOBE NEWSWIRE/ Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in t
Read more →OCGNHistogenics Corporation Announces the Appointment of David Gill to its Board of Directors and Chairman of Audit Committee Financial Expert to Serve as Chairman of Histogenics Audit Committee WALTHAM, MA
Histogenics Corporation Announces the Appointment of David Gill to its Board of Directors and Chairman of Audit Committee Financial Expert to Serve as Chairman of Histogenics Audit Committee WALTHAM, MA, February 2, 2015 /PRNewswire/ Histogenics Corporation (Nasdaq: HSGX), a re
Read more →Competitive Position
How OCGN ranks across every disease it competes inCompetitive Position is a premium feature
See how OCGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial